Hydrogel-based Drug Delivery System Market (2026 - 2033)

Hydrogel-based Drug Delivery System Market Summary

The global hydrogel-based drug delivery system market size was valued at USD 8.4 billion in 2025 and is projected to grow from USD 9.0 billion in 2026 to USD 14.1 billion by 2033, at a CAGR of 6.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. Key factors driving the growth of the global market for hydrogel-based drug delivery system include the biocompatibility and biodegradable properties coupled with a controlled release profile, which makes hydrogel a potential drug delivery system.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Due to the growing inclination towards controlled release drug delivery over conventional systems, hydrogels are widely used for achieving controlled drug release of incorporated drugs.

Due to their immense biocompatibility, physiochemical tolerability, and drug protection, hydrogels are used for controlled and targeted drug delivery. Furthermore, these properties of hydrogels are useful in encapsulating proteins and nucleic acids, contributing to increasing innovations in hydrogel-based drug delivery systems. Hydrogels are preferred drug carriers due to features such as easy production and self-application.

In recent years, the hydrogel-based drug delivery systems industry has experienced increasing investment in R&D in search of innovative drug delivery methods and diagnostics. Development in polymer science has led to the formation of biopolymers that provide a biocompatible and biodegradable framework for hydrogels, promoting their usage in efficient and targeted drug delivery. Therefore, there has been a noteworthy rise in enhancements in R&D activities.

Analyst Perspective

The market is poised for robust growth, supported by the increasing demand for targeted and controlled drug delivery, rising prevalence of chronic diseases, and ongoing advancements in biomaterials and pharmaceutical formulations. Hydrogel-based delivery systems are gaining widespread adoption due to their excellent biocompatibility, high water content, and ability to provide sustained and site-specific drug release, improving therapeutic efficacy while minimizing adverse effects. Expanding research in tissue engineering, regenerative medicine, and injectable hydrogel technologies is further broadening the market's application scope. As healthcare providers seek safer, more effective, and minimally invasive treatment solutions, companies that focus on advanced hydrogel formulations, multifunctional delivery platforms, and strategic collaborations are expected to strengthen their competitive position.

Polymer Origin Insights

Synthetic hydrogels dominated the market and accounted for a share of over 45.0% in 2025. Hydrogel polymer origins are classified into natural, synthetic, and hybrid. A hydrogel-based drug delivery system is made from synthetic polymers as they have higher drug absorbing capacity, improved mechanical capacity, and enhanced lifetime. Some of the widely used synthetic polymers in drug delivery applications are polyethylene glycol (PEG) and poly (lactic-co-glycolic acid) (PLGA).

The natural polymers segment is expected to grow significantly from 2026 to 2033. Natural polymers such as xanthan gum, alginate, pectin, dextran, and chitosan are increasingly being explored due to their nontoxicity, easy availability, and biodegradability characteristics. Extensive research is being undertaken to investigate the definite applications of natural polysaccharides in drug delivery, which is expected to drive demand for this segment during the forecast period.

Delivery Route Insights

The hydrogel-based ocular drug delivery systems accounted for the largest revenue share in 2025. A growing number of people impacted by ophthalmic disorders and problems have developed a need for more effective drug delivery systems, as limitations such as low ocular bioavailability are identified in conventional systems. This has encouraged a lot of research and development in this domain, which has resulted in new product developments and innovation. For instance, in October 2025, researchers in Germany developed a hybrid gelatin–alginate hydrogel system capable of co-delivering dual antiglaucoma drugs with extended release profiles lasting several weeks. The system integrates microparticle–hydrogel architecture to improve stability and controlled diffusion in ocular environments.

The topical hydrogel segment is expected to register the fastest CAGR from 2026 to 2033. Administering drugs topically is an efficient and affordable way to provide therapeutic substances to specific areas. Novel hydrogels have broad applications in treating pediatric, geriatric, and pregnant patients. These consist of nanoparticles, nanoemulsions, micro emulsions, liposomes, self-nano emulsifying drug delivery systems, cubosomes, and similar structures. Therefore, R&D in this drug delivery system is a key factor for market growth. For instance, in July 2025, Chinese research institutions developed a pH-responsive hydrogel drug delivery system that releases antimicrobial agents selectively in infected tissue environments, improving targeted therapy efficiency and reducing systemic toxicity.

Regional Insights

The hydrogel-based drug delivery system industry in North America dominated the global market, with a revenue share of 40.0% in 2025.

To learn more about this report, Download Free Sample Report

U.S. Hydrogel-based Drug Delivery System Market Trends

The hydrogel-based drug delivery system industry in the U.S. held the largest revenue share in the North American region of around 80.0% in 2025. This is primarily due to several key companies and major pharmaceutical industry participants in the country. In addition, growing investment in R&D in the U.S. has resulted in innovation and new product development, which is expected to propel growth in the coming years.

Europe Hydrogel-based Drug Delivery System Market Trends

The hydrogel-based drug delivery system industry in Europe is identified as a lucrative region for this industry. Increased research on improving hydrogel-based protein delivery and a rise in investment in developing newer hydrogel-based drug delivery solutions are key factors driving this growth.

The Germany hydrogel-based drug delivery system industry is expected to experience significant growth from 2026 to 2033. This is primarily due to enhanced research and development activities needed to develop novel drug delivery systems. The research is primarily related to tumor therapy and the uninterrupted delivery of anti-infective while dealing with biological barriers.

Asia Pacific Hydrogel-based Drug Delivery System Market Trends

The hydrogel-based drug delivery system industry in Asia Pacific is anticipated to witness the fastest growth from 2026 to 2033 owing to a large target population, increased accessibility of the healthcare industry, rising demand for improved medical care in various therapeutic fields, and a growing emphasis on lowering healthcare expenses.

China hydrogel-based drug delivery industry is expected to grow rapidly from 2026 to 2033, owing to increasing investments by global companies in China’s pharmaceutical industries searching for novel diagnostics and drug delivery systems. In addition, the growing prevalence of health conditions such as inflammatory bowel disease (IBD) has been generating greater demand for advanced drug delivery technologies.

Key Hydrogel-based Drug Delivery System Company Insights

Some key companies in the market include GALDERMA; Johnson & Johnson; Bausch + Lomb; Medtronic; and Ocular Therapeutix, Inc. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other emerging and prominent industry participants.

• Ocular Therapeutix, Inc., is a biopharmaceutical company that specializes in creating, advancing, and marketing new treatments for eye disorders. It employs its own bioresorbable hydrogel-based formulation technology, ELUTYX. The company has manufacturing facilities in Massachusetts.

Key Hydrogel- based Drug Delivery System Companies:

The following key companies have been profiled for this study on the hydrogel-based drug delivery system market:

• GALDERMA

• Johnson & Johnson

• Bausch + Lomb

• Ocular Therapeutix, Inc.

• Merck KGaA

• Evonik Industries AG

• Ashland Inc.

• Corbion N.V.

• AbbVie Inc.

• Biogelx Ltd.

Recent Developments

• In November 2025, a review published in the Journal of Clinical Medicine highlighted hydrogel-based delivery systems for non-opioid analgesics, showing growing clinical interest in hydrogel platforms for pain management applications. The study emphasizes hydrogels as carriers for controlled release of NSAIDs and neurological drugs.
• In September 2025, researchers published a new hydrogel drug delivery platform based on self-assembling peptide networks that significantly slows drug release and enables long-acting therapeutic effects. The system improves sustained release performance and reduces burst release, a long-standing limitation in injectable hydrogel carriers.

Global Hydrogel-based Drug Delivery System Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hydrogel-based drug delivery system market report based on polymer origin, delivery route, and region:

• Polymer Origin Outlook (Revenue, USD Billion, 2021 - 2033)

  • Natural

  • Synthetic

  • Hybrid

• Delivery Route Outlook (Revenue, USD Billion, 2021 - 2033)

  • Subcutaneous

  • Ocular

  • Oral Cavity

  • Topical

  • Other

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait